Saved in:
Bibliographic Details
Main Authors: Suo, Qishan, Yue, Yang, Wang, Jing, Wu, Ning, Geng, Lihua, Zhang, Quanbin
Format: Artículo científico
Language:en
Published: Food research international (Ottawa, Ont.) 2026
Subjects:
Online Access:https://pubmed.ncbi.nlm.nih.gov/41763799/
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1868266079670763520
author Suo, Qishan
Yue, Yang
Wang, Jing
Wu, Ning
Geng, Lihua
Zhang, Quanbin
author_facet Suo, Qishan
Yue, Yang
Wang, Jing
Wu, Ning
Geng, Lihua
Zhang, Quanbin
Suo, Qishan
Yue, Yang
Wang, Jing
Wu, Ning
Geng, Lihua
Zhang, Quanbin
collection PubMed - marine biology
contents Discovery and molecular mechanism of a novel antihypertensive peptide from Chlamydomonas reinhardtii based on molecular docking, molecular dynamics simulation, in vitro, and in vivo analysis. Suo, Qishan Yue, Yang Wang, Jing Wu, Ning Geng, Lihua Zhang, Quanbin Animals Antihypertensive Agents Molecular Dynamics Simulation Rats, Inbred SHR Molecular Docking Simulation Chlamydomonas reinhardtii Angiotensin-Converting Enzyme Inhibitors Bioactive Peptides, Dietary Rats Hypertension Peptides Male Lisinopril Chlamydomonas reinhardtii, a nutrient-rich microalga and emerging food resource, remains largely unexplored as a source of bioactive peptides. In this study, eight protease hydrolysates were prepared from C. reinhardtii. Among these, the alkaline protease hydrolysate (CRPA) demonstrated the most potent activity, exhibiting strong angiotensin-I converting enzyme (ACE) inhibitory activity in vitro and significant in vivo antihypertensive activity in spontaneously hypertensive rats (SHRs), with the effective dose corresponding to an estimated human-equivalent dose of 16 mg/kg/day. Using bioassay-guided isolation strategy, the first ACE-inhibitory peptide IDYRY (ID-5) was identified from C. reinhardtii, exhibiting an IC value of 18.54 ± 5.57 μM. ID-5 was characterized as a noncompetitive ACE inhibitor with confirmed antihypertensive activity both in vitro and in vivo. Molecular dynamics simulations revealed that ID-5 forms unique hydrogen bonds with Asp415 and Arg522, distinguishing its binding mechanism from that of captopril or lisinopril. Collectively, these findings highlight the enhanced bioactivity of CRPA and position C. reinhardtii as a sustainable microalgal source for developing functional foods and nutraceuticals aimed at blood pressure management.
format Artículo científico
id pubmed_41763799
institution PubMed
language en
publishDate 2026
publisher Food research international (Ottawa, Ont.)
record_format pubmed
spellingShingle Discovery and molecular mechanism of a novel antihypertensive peptide from Chlamydomonas reinhardtii based on molecular docking, molecular dynamics simulation, in vitro, and in vivo analysis.
Suo, Qishan
Yue, Yang
Wang, Jing
Wu, Ning
Geng, Lihua
Zhang, Quanbin
Animals
Antihypertensive Agents
Molecular Dynamics Simulation
Rats, Inbred SHR
Molecular Docking Simulation
Chlamydomonas reinhardtii
Angiotensin-Converting Enzyme Inhibitors
Bioactive Peptides, Dietary
Rats
Hypertension
Peptides
Male
Lisinopril
Discovery and molecular mechanism of a novel antihypertensive peptide from Chlamydomonas reinhardtii based on molecular docking, molecular dynamics simulation, in vitro, and in vivo analysis. Suo, Qishan Yue, Yang Wang, Jing Wu, Ning Geng, Lihua Zhang, Quanbin Animals Antihypertensive Agents Molecular Dynamics Simulation Rats, Inbred SHR Molecular Docking Simulation Chlamydomonas reinhardtii Angiotensin-Converting Enzyme Inhibitors Bioactive Peptides, Dietary Rats Hypertension Peptides Male Lisinopril Chlamydomonas reinhardtii, a nutrient-rich microalga and emerging food resource, remains largely unexplored as a source of bioactive peptides. In this study, eight protease hydrolysates were prepared from C. reinhardtii. Among these, the alkaline protease hydrolysate (CRPA) demonstrated the most potent activity, exhibiting strong angiotensin-I converting enzyme (ACE) inhibitory activity in vitro and significant in vivo antihypertensive activity in spontaneously hypertensive rats (SHRs), with the effective dose corresponding to an estimated human-equivalent dose of 16 mg/kg/day. Using bioassay-guided isolation strategy, the first ACE-inhibitory peptide IDYRY (ID-5) was identified from C. reinhardtii, exhibiting an IC value of 18.54 ± 5.57 μM. ID-5 was characterized as a noncompetitive ACE inhibitor with confirmed antihypertensive activity both in vitro and in vivo. Molecular dynamics simulations revealed that ID-5 forms unique hydrogen bonds with Asp415 and Arg522, distinguishing its binding mechanism from that of captopril or lisinopril. Collectively, these findings highlight the enhanced bioactivity of CRPA and position C. reinhardtii as a sustainable microalgal source for developing functional foods and nutraceuticals aimed at blood pressure management.
title Discovery and molecular mechanism of a novel antihypertensive peptide from Chlamydomonas reinhardtii based on molecular docking, molecular dynamics simulation, in vitro, and in vivo analysis.
topic Animals
Antihypertensive Agents
Molecular Dynamics Simulation
Rats, Inbred SHR
Molecular Docking Simulation
Chlamydomonas reinhardtii
Angiotensin-Converting Enzyme Inhibitors
Bioactive Peptides, Dietary
Rats
Hypertension
Peptides
Male
Lisinopril
url https://pubmed.ncbi.nlm.nih.gov/41763799/